ENYO Pharma is a technology company.
ENYO Pharma has raised $75.0M across 2 funding rounds.
ENYO Pharma has raised $75.0M in total across 2 funding rounds.
ENYO Pharma is a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics with fibrolytic and anti-inflammatory properties, primarily targeting diseases with impaired kidney function such as Chronic Kidney Disease (CKD), Alport syndrome, and Metabolic dysfunction-associated steatohepatitis (MASH).[1][2][4] Its lead compound, Vonafexor (EYP001), is an oral, non-steroidal FXR agonist in Phase 2 trials for CKD in MASH patients, Alport syndrome, and related liver-kidney conditions, showing benefits in eGFR, inflammation, and fibrosis; a second candidate, EYP651, is in Phase 1/2 for CKD, diabetic kidney disease (DKD), and renal fibrosis.[1][2][5] The company serves patients with rare and chronic kidney disorders, addressing unmet needs in fibrosis and inflammation where current treatments fall short, with a pipeline extending to early programs in infectious diseases like RSV and oncology via immunogenic cell death inducers.[4][6]
Growth momentum includes multiple completed clinical studies (9 for Vonafexor), ongoing Phase 2 trials, and a €22M Series A financing in 2017 led by Sofinnova Partners to advance hepatitis B and influenza programs, alongside partnerships with Novadiscovery, Charles River, and the Swiss Institute of Bioinformatics.[3][8] Headquartered in Lyon, France, with operations in Melbourne, Australia, ENYO focuses on kidney-liver axis diseases affecting 30-50% of MASH patients with CKD.[1][4]
ENYO Pharma was founded in 2014 in Lyon, France, by Inserm scientists Patrice André and Vincent Lotteau—experts in virus-host protein interactions from the French Infectiology Research Center—and industry veteran Jacky Vonderscher, PhD, who serves as CEO and co-founder with prior successes at Roche and Novartis (e.g., Sandimmun Neoral, Myfortic, Certican, Afinitor).[1][3] The idea emerged from a unique drug discovery platform inspired by virus biomimetism, targeting host-virus protein interactions rather than viral components to disrupt replication, marking a paradigm shift from traditional antivirals.[1][3]
Early traction came via the EU's Horizon 2020 MIMESIS program (2016-2018), which validated the platform for novel targets and chemistries against viruses like RSV, Zika, influenza, and tuberculosis, while pivoting from initial infectious disease focus (e.g., hepatitis B Phase 1 plans post-€22M raise) to kidney and liver therapeutics with Vonafexor.[3][6] This evolution humanizes ENYO as a bridge between academic innovation and clinical biotech, now a Lyonbiopôle member advancing rare disease programs.[4]
ENYO Pharma rides the wave of precision therapeutics for the kidney-liver axis, where bidirectional pathways link 30-50% of MASH cases to CKD, amid rising global burdens of metabolic, diabetic, and rare renal diseases (e.g., Alport syndrome, ADPKD).[1][4] Timing aligns with FXR agonist momentum post-semaglutide successes in metabolic space, but ENYO's non-bile acid, kidney-beneficial profile fills gaps in fibrosis-focused treatments, with Phase 2 data supporting 48% PTSR benchmarks for CKD drugs.[5]
Market forces favor it: aging populations drive CKD prevalence (affecting millions), unmet needs in rare diseases qualify for incentives, and biomimetism enables diversification into antivirals/oncology amid post-pandemic RSV demand.[2][6][7] ENYO influences the ecosystem by validating host-targeted platforms, partnering with CROs/academia, and contributing to Lyonbiopôle's biotech cluster, potentially reshaping FXR class utility beyond liver to renal impairment.[3][4][8]
ENYO's near-term catalysts include Phase 2 readouts for Vonafexor in Alport/CKD-MASH and EYP651 advancement in DKD, with early RSV/oncology programs poised for out-licensing via its partnering-friendly platform.[1][2][6] Trends like AI-driven target ID (echoing MIMESIS) and combo therapies with GLP-1s (hinted in patents) will shape its path, boosting LoA amid high Phase II success rates.[5][7]
Influence may evolve through big-pharma deals, expanding from niche kidney rare diseases to blockbuster metabolic indications, solidifying ENYO as a fibrolytic innovator in an underserved organ axis—transforming its 2014 viral origins into sustained clinical impact.[3][8]
ENYO Pharma has raised $75.0M in total across 2 funding rounds.
ENYO Pharma's investors include Andera Partners, Earlybird Venture Capital, Kurma Partners, OrbiMed, Pfizer Venture Investments, Pureos Bioventures, SR One, Third Rock Ventures, Wellington Partners, Vincent Brichard.
ENYO Pharma has raised $75.0M across 2 funding rounds. Most recently, it raised $28.0M Series C in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $28.0M Series C | Andera Partners, Earlybird Venture Capital, Kurma Partners, OrbiMed, Pfizer Venture Investments, Pureos Bioventures, SR One, Third Rock Ventures, Wellington Partners, Vincent Brichard | |
| Jun 1, 2018 | $47.0M Series B | Andera Partners, Earlybird Venture Capital, Kurma Partners, OrbiMed, Pfizer Venture Investments, Pureos Bioventures, SR One, Third Rock Ventures, Wellington Partners, Vincent Brichard |